Oxford Gene Technology successfully completes world's largest copy number variation study
Oxford Gene Technology (OGT) has successfully completed processing more than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium (WTCCC), the world’s largest CNV study involving a collaboration of 24 human geneticists. The project analysed DNA samples from patients to identify genetic variants that play a role in various human diseases, including bipolar disorder, Crohn’s disease, coronary artery disease, type 1 and 2 diabetes, rheumatoid arthritis, breast cancer and hypertension.
OGT processed over 20,000 samples in 20 weeks, using state-of-the-art automated processing to achieve exceptional data quality from whole-genome human CNV-focussed microarrays developed by Agilent. According to the company, over 40 quality control checks have been performed and recorded for each sample during the workflow, producing documented evidence of the excellent QC metrics that have been met.
"In order to characterise genetic variants, reproducible performance and reliable processing of the high resolution microarrays is essential. This project demanded high quality data generated to tight deadlines, and we were very pleased with its rapid progress," said Dr Matt Hurles of the Wellcome Trust Sanger Institute. "Our preliminary estimate is that approximately 20-30 % of the ~11,000 loci targeted on the array we have designed are both polymorphic in our British study population and provide sufficient data quality to assign integer copy numbers to individuals."
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
New dyes detect disease through heartbeat signals
Predicting the mode of action of new anti-cancer drugs with AI - Acceleration of the development of new cancer drugs
Chemists develop MRI-like technique to detect what ails batteries
New corona mass test up to 100 times more sensitive than rapid antigen tests - The innovative corona test "LAMP-Seq"
A more complete picture of the nano world
Nimbus Discovery and Proteros enter into multi-target X-ray protein crystallography collaboration
Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Mode of action of the vaccine adjuvant flagellin in fusion proteins has been clarified
Alternative methods replace animal experiments: 20 years successful work by ZEBET within BfR - ZEBET celebrates its anniversary with an international symposium at BfR in Berlin
Imaging the smallest atoms provides insights into an enzyme's unusual biochemistry - This could help in the design of enzymes for the chemical industry
